Patients who developed myocarditis within the first month of receiving immune checkpoint
inhibitor therapy for cancer were more likely to die of myocarditis, according to an #AACR26 presentation by @HMAbushukair of @StephensonCC. https://t.co/peqQ3bped9 https://t.co/4gyic9DtUT